西地那非治疗肺动脉高压的疗效及安全性研究

牛攀霞

（西安医学院第二附属医院，陕西 西安，710038）

浏览次数：103次 下载次数：345次

摘要：

目的 探索西地那非治疗肺动脉高压的临床效果及安全性。方法 选择我院收治的肺动脉高压患者120 例，随机分为研 究组与对照组，各60 例。对照组给予常规抗心律治疗，研究组给予常规治疗+西地那非口服治疗。比较两组患者治疗效果。结果 治疗后，两组患者6 min 步行距离、Borg 呼吸困难指数、肺动脉高压功能分级、心功能分级均显著改善，且研究组均显著优 于对照组，差异显著（P<0.05）。研究组的不良反应发生率高于对照组（P<0.05）。结论 西地那非血管扩张效果显著，可有效降 低患者肺动脉压力，改善患者心功能，并且对患者体循环无影响，安全高效，值得临床大力推广。

关键词：西地那非；肺动脉高压；安全性

中图分类号：R543文献标志码：A文章编号：2096-1413(2018)03-0015-02

Clinical efficacy and safety of sildenafil in the treatment of pulmonary hypertension
NIU Pan-xia
(the Second Affiliated Hospital of Xi``an Medical University, Xi``an 710038, China)

ABSTRACT: Objective To explore the clinical effect and safety of sildenafil on pulmonary hypertension. Methods A total of 120 patients with pulmonary hypertension were randomly divided into study group and control group, with 60 cases in each group. The control group was treated with routine antiarrhythmic therapy, and the study group was given routine treatment with sildenafil oral therapy. The treatment effects were compared between the two groups. Results After treatment, 6 min walking distance, Borg dyspnea index, pulmonary hypertension function grade and cardiac function grade in the two groups significantly improved, and those of the study group were better than the control group, the differences were statistically significant (P<0.05). The incidence of adverse reactions in the study group was higher than that in the control group (P<0.05). Conclusion The sildenafil has remarkable vascular dilatation effect, it can effectively reduce the patients`` pulmonary artery pressure, improve cardiac function of PAH patients, and no effect on the patients`` systemic circulation, which is safe, efficient and worthy of clinical promotion.
KEYWORDS: sildenafil; pulmonary hypertension; safety

参考文献：
[1] 闫芳,夏宇,李威,等.西地那非治疗肺动脉高压的疗效及安全性研究[J].中国临床药理学杂志,2014,30(10):877-879.
[2] 高淑强,巨容,胡旭红,等.高频振荡通气联合西地那非治疗新生儿持续肺动脉高压的疗效观察[J].中华实用儿科临床杂志,2015,30(2):114-117.
[3] 杨朝,葛利军,赵霞,等.西地那非治疗慢性阻塞性肺疾病相关肺动脉高压的疗效[J].中国老年学杂志,2015,35(5):1156-1157.
[4] 高伟,顾红,胡大一,等.2015 年先天性心脏病相关性肺动脉高压诊治中国专家共识[J].中国介入心脏病学杂志,2015,35(2):61.
[5] 刘士敬,李建宇.国内外"超说明书用药"的状况与分析[J].中国中医药现代远程教育,2014,16(1):142-143.
[6] 邓贵华,杨亮,陈小葵.等.西地那非超说明书用药回顾性调查[J].医药导报,2017,36(1):44-47.
[7] 范顺娟,毛小运.西地那非联合阿托伐他汀钙治疗COPD 相关肺动脉高压的疗效探讨[J].中外医疗,2015,34(14):1-2.
[8] 夏燕亮,马如海,陈宏.西地那非治疗高原地区先天性心脏病合并重度肺动脉高压的疗效和安全性探讨[J].中国循环杂志,2014,29(9):702-705.
[9] 高汉华,刘映峰,钟华英,等.川芎嗪联合西地那非对原发性肺动脉高压导致右心室重塑的影响[J].中国老年学杂志,2014,34(9):2383-2385.
[10] 李增波,冯伟,欧阳熠烨.西地那非联合常频机械通气治疗新生儿 持续性肺动脉高压的疗效观察[J].中南医学科学杂志,2015,43(4):418-419.